Do Children and Adolescents With ADHD Respond Differently to Atomoxetine? - 09/08/11
, Christopher Kratochvil, M.D., Jeffrey H Newcorn, M.D., Haitao Gao, Ph.D.ABSTRACT |
Objective |
Controversy exists over changes in tolerability and response to medications across the life span. Here the authors report data contrasting the efficacy and tolerability of atomoxetine between children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Method |
Data were analyzed for children ages 6-11 (510 atomoxetine, 341 placebo) and adolescents ages 12-17 (107 atomoxetine, 69 placebo) with DSM-IV-defined ADHD enrolled in similarly designed, double-blind, placebo-controlled trials. Efficacy measures included response rates, times to response, and mean changes from baseline to endpoint in the ADHD Rating Scale, Conners’ Parent Rating Scale, and Clinical Global Impressions.
Results |
Adolescents had lower baseline ADHD scores compared with children. There were no statistically significant differences in the overall effects on ADHD symptoms, response rates, or time to response between age groups. Children, but not adolescents, had higher rates of somnolence and headache relative to placebo. No other clinically meaningful treatment differences were seen in adverse event rates, vital signs, weight, height, laboratory values, or ECG between children and adolescents.
Conclusions |
Acute atomoxetine treatment appears to be equally effective and tolerated in children and adolescents. These findings suggest that pharmacological differences in tolerability or ADHD symptom response are negligible between children and adolescents.
Le texte complet de cet article est disponible en PDF.Key Words : age, atomoxetine, adolescents, attention-deficit/hyperactivity disorder, children
Plan
| Research funded by Eli Lilly and Company. The authors acknowledge Nikki Wright and Kurt Baker for their contributions. |
|
| Disclosure: Drs. Wilens, Kratochvil, and Newcorn were paid consultants and/or investigators for studies sponsored by Eli Lilly & Company. Dr. Wilens is a recipient of research grants from Cephalon, GlaxoSmithKline, Janssen, Lilly, McNeil, NeuroSearch, New River Pharmaceuticals, Novartis, and Shire; a consultant for Abbott, Cephalon, Lilly, McNeil, NeuroSearch, Novartis, Sanofi-Synthelabo, and Shire; and a speaker for Janssen, Lilly, McNeil, Novartis, and Shire. Dr. Kratochvil is a recipient of research grants from Cephalon, GlaxoSmithKline, Lilly, and McNeil; a consultant for Lilly; and a speaker for Lilly and Novartis. Dr. Newcorn is a recipient of research grants from Lilly, McNeil, and Shire; a consultant for Lilly and Novartis; a member of the advisory board for Celltech, Lilly, McNeil, Novartis, and Shire; and a speaker for Janssen, Lilly, McNeil, Novartis, and Shire. Dr. Gao is an employee and shareholder of Eli Lilly & Company. |
Vol 45 - N° 2
P. 149-157 - février 2006 Retour au numéro
Article précédent
- Combination Lithium and Divalproex Sodium in Pediatric Bipolar Symptom Restabilization
- Robert L Findling, Nora K McNamara, Robert Stansbrey, Barbara L Gracious, Resaca E Whipkey, Christine A Demeter, Michael D Reed, Eric A Youngstrom, Joseph R Calabrese
- Depression Experience Journal: A Computer-Based Intervention for Families Facing Childhood Depression
- David Ray DeMaso, Nicole Eldridge Marcus, Carolyn Kinnamon, Joseph Gonzalez-Heydrich
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?